Table S2.
Demographics of moderate-to-severe COPD patients with or without bronchiectasis
| Values | All patients | COPD without bronchiectasis | COPD with bronchiectasis | P-value |
|---|---|---|---|---|
| Subjects, n (%) | 127 (100.0) | 54 (42.5) | 73 (57.5) | |
| Age* | 71.5 ± 7.6 | 69.8 ± 8.1 | 72.9 ± 7.0 | 0.024 |
| Male | 107 (84.3) | 47 (87.0) | 60 (82.2) | 0.459 |
| Smoking status | 0.830 | |||
| Current | 43 (34.7) | 18 (34.0) | 25 (35.2) | |
| Former | 55 (44.3) | 25 (47.2) | 30 (42.3) | |
| Never | 26 (21.0) | 10 (18.9) | 16 (22.5) | |
| Pack-years smoked* | 30.3 ± 25.2 | 27.6 ± 24.4 | 32.6 ± 26.0 | 0.345 |
| GOLD grade | 0.387 | |||
| Grade 2 | 107 (84.2) | 45 (83.3) | 62 (84.9) | |
| Grade 3 | 18 (14.2) | 9 (16.7) | 9 (12.3) | |
| Grade 4 | 2 (1.6) | 0 (0.0) | 2 (2.7) | |
| BMI*, kg/m2 | 22.7 ± 3.4 | 23.1 ± 3.1 | 22.3 ± 3.6 | 0.194 |
| Previous TB | 40 (31.5) | 8 (14.8) | 32 (43.8) | 0.001 |
| Pneumoconiosis | 8 (6.3) | 5 (9.3) | 3 (4.1) | 0.490 |
| MMRC§ | 23/51/16/25/9 | 10/23/6/9/5 | 13/28/10/16/4 | 0.939 |
| CAT score* | 18.8 ± 9.9 | 18.7 ± 10.7 | 18.9 ± 9.3 | 0.904 |
| Respiratory symptoms | ||||
| Cough | 89 (70.1) | 34 (63.0) | 55 (75.3) | 0.132 |
| Sputum | 96 (75.6) | 39 (72.2) | 57 (78.1) | 0.447 |
| Dyspnea | 71 (55.9) | 27 (50.0) | 44 (60.3) | 0.249 |
| History of pneumonia | 12 (9.8) | 6 (11.5) | 6 (8.6) | 0.717 |
| History of asthma | 27 (22.1) | 14 (26.9) | 13 (18.6) | 0.451 |
| Exacerbations | 7 (5.6) | 3 (5.6) | 4 (5.6) | 0.985 |
| Steroid treatment | 3 (2.4) | 1 (1.9) | 2 (2.8) | 0.727 |
| Hospital admissions | 5 (4.0) | 2 (3.7) | 3 (4.2) | 0.883 |
| Death, n (%) | 4 (3.2) | 3 (5.6) | 1 (1.4) | 0.182 |
| WBC*, ×103 μL | 6.8 ± 1.9 | 7.0 ± 2.0 | 6.7 ± 1.8 | 0.337 |
| Segmenter neutrophils*, μL | 4,063.4 ± 1,490.7 | 4,120.0 ± 1,630.1 | 4,021.6 ± 1,388.8 | 0.715 |
| Eosinophils*, μL | 186.3 ± 215.3 | 169.4 ± 130.5 | 198.9 ± 261.1 | 0.448 |
| Albumin*, g/dL | 4.1 ± 0.3 | 4.1 ± 0.4 | 4.1 ± 0.3 | 0.452 |
| IL-6*, pg/mL | 2.6 ± 3.1 | 2.1 ± 2.6 | 3.0 ± 3.4 | 0.145 |
| IL-8*, pg/mL | 16.5 ± 17.1 | 15.3 ± 13.0 | 17.4 ± 19.9 | 0.526 |
| CRP*, mg/dL | 0.3 ± 0.5 | 0.2 ± 0.3 | 0.3 ± 0.6 | 0.119 |
| BDR, FEV1, n (%) | 31 (24.4) | 19 (35.2) | 12 (16.4) | 0.015 |
| BDR, FVC, n (%) | 40 (31.5) | 18 (33.3) | 22 (30.1) | 0.701 |
| FVC*, % | 86.3 ± 14.8 | 85.3 ± 15.2 | 87.0 ± 14.5 | 0.518 |
| FEV1*, % | 64.0 ± 12.3 | 64.7 ± 11.8 | 63.5 ± 12.6 | 0.573 |
| FEV1/FVC*, ratio | 54.5 ± 9.0 | 56.0 ± 7.6 | 53.5 ± 9.8 | 0.122 |
| Mean WA* | 70.2 ± 5.4 | 70.8 ± 4.6 | 69.7 ± 5.8 | 0.244 |
| E/I-ratioMLD* | 1.0 ± 0.0 | 0.9 ± 0.0 | 1.0 ± 0.0 | 0.016 |
| EI* | 9.7 ± 8.5 | 9.5 ± 7.8 | 9.9 ± 9.1 | 0.769 |
Notes: Data shown are frequencies; those in parentheses are percentages.
Data shown are the mean ± SD values, unless indicated otherwise.
Data shown as number of scores for each mMRC grade from 0–4, respectively. Data in bold are statistically significant.
Abbreviations: BDR, bronchodilator reversibility; BMI, body mass index; CAT, COPD assessment test; CRP, C-reactive protein; EI, emphysema index; E/I-ratioMLD, expiratory to inspiratory ratio of mean lung density; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IL, interleukin; MMRC, modified Medical Research Council; TB, tuberculosis; WA, wall area; WBC, white blood cell.